Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2- Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication

CONCLUSION: We mapped frequency and types of ribociclib-induced CAEs. An interdisciplinary management of CAEs incorporated into routine care may reduce the rate of drug discontinuation thus potentially contributing to better long-term outcomes.PMID:38242689 | DOI:10.1093/oncolo/oyae004

Source: The Oncologist - January 19, 2024 Category: Cancer & Oncology Authors: Riccardo Giovanni Borroni Michela Bartolini Mariangela Gaudio Flavia Jacobs Chiara Benvenuti Riccardo Gerosa Paola Tiberio Sofia Ada Assunta Maria Manara Alessandra Solferino Armando Santoro Rita De Sanctis Source Type: research